Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 367, Issue 1, 2003, Pages 56-67

  Efferth, Thomas ^a   Sauerbrey, Axel ^b   Halatsch, Marc Eric ^c   Ross, Douglas D ^d   Gebhart, Erich ^e  

^a Virtual Campus Rhineland Palatinate ^*  (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Hierarchical cluster analysis; Microarray analysis; Multidrug resistance; P53

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CEPHALOTAXINE; CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P; HOMOHARRINGTONINE; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BREAST CANCER; CELL LINE; CELL PROLIFERATION; CEPHALOTAXUS HAINANENSIS; CONTROLLED STUDY; DRUG RESPONSE; GENE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR MODEL; MULTIDRUG RESISTANCE; MUTATION; TREE; TUMOR CELL LINE; TUMOR GROWTH;

CELL DIVISION; CEPHALOTAXUS; CLUSTER ANALYSIS; CONIFEROPHYTA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, MDR; GROWTH INHIBITORS; HARRINGTONINES; HL-60 CELLS; HUMANS; JURKAT CELLS; RECEPTORS, GROWTH FACTOR; RECEPTORS, MITOGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0037280015     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0632-0     Document Type: Article

References (48)

1. Alley MC, Scudiero DA, Monks A, et al. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601
2. Baguely BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP (1989) Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 25:263-269
3. Bell BA, Chang MN, Weinstein HJ (2001) A phase II study of homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. Med Pediatr Oncol 37:103-107
4. Brugger D, Herbart H, Gekeler V, et al. (1999) Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts. Leuk Res 23:467-475
5. Cai Z, Lin M, Wuchter C, Ruppert V, Dörken B, Ludwig WD, Karawajew L (2001) Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 15:567-574
6. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670
7. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445-3453
8. Efferth T (2001) The human ATP-binding cassette transporter gene family: from the bench to the bedside. Curr Mol Med 1:45-65
9. Efferth T, Fabry U, Osieka R (1996) Anti-Fas/Apo-1 monoclonal antibody CH-11 depletes glutathione and kills multidrug-resistant human leukemic cells. Blood Cells Mol Dis 22:2-9
10. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R (2002) Activity of drugs from traditional Chinese medicine towards sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 28:160-168
11. El Deiry WS (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9:79-87
12. Feldman E, Arlin Z, Ahmed T, et al. (1992) Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 6:1185-1188
13. Fountzilas G, Lim LO, Yunis AA (1988) The inhibitory effects of teniposide and homoharringtonine on the growth of pancreatic carcinoma cells in vitro. Anticancer Res 8:343-346
14. Fresno M, Jimenez A, Vazquez D (1977) Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 72:323-330
15. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD, Weiner LM (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220
16. Halatsch ME, Schmidt U, Bötefür IC, Holland JF, Ohnuma T (2000) Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg 92:297-305
17. Halatsch ME, Schmidt U, Bötefür IC, Holland JF, Ohnuma T (2001) Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line. Anticancer Res 21:189-195
18. Han J (1988) Traditional Chinese medicine and the search for new antineoplastic drugs. J Ethnopharmacol 24:1-17
19. Huang CC, Han CS, Yue X, Shen CM, Wang SW, Wu FG, Xu B (1983) Cytotoxicity and sister chromatid exchanges induced in vitro by six drugs developed in the People's Republic of China. J Natl Cancer Inst 71:841-847
20. Huang HJS, Nagane M, Klingbeil CK, et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927-2935
21. Inoue S, Salah-Eldin AE, Omoteyama K (2001) Apoptosis and anticancer drug resistance. Hum Cell 14:211-221
22. Kantarjian HM, Talpaz M, Smith TL, et al. (2000) Homoharringtonine and low-dose cytarabine in the management of late chronic-phase myelogenous leukemia. J Clin Oncol 18:3513-3521
23. Kimmig A, Gekeler V, Neumann M, et al. (1990) Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50:6793-6799
24. Kohn KW, Jackman J, O'Connor P (1994) Cell cycle control and cancer chemotherapy. Cell Biochem 54:440-452
25. Libermann TA, Nusbaum HR, Razon N, et al. (1985) Amplification, enhanced expression and possible rearrangement of EGFR receptor gene in primary human brain tumours of glial origin. Nature 313:144-147
26. Ling YH, Tseng MT, Harry JI (1989) Effects of homoharringtonine on protein glycosylation in human bladder carcinoma cell T-24. Cancer Res 49:76-80
27. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP (2000) Mechanism of action of camptothecin. Ann NY Acad Sci 922:1-10
28. Löwenberg B, Putten WLJ van, Touw IP, Delwel R, Santini V (1993) Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New Engl J Med 328:614-619
29. Luker KE, Pica CM, Schreiber RD, Piwnica-Worms D (2001) Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res 61:6540-6547
30. Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW (1987) Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res 47:2050-2055
31. Martin NM (2001) DNA repair inhibition and cancer therapy. J Photochem Photobiol B 63:162-170
32. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O (1995) Sensitization of human renal cell carcinoma cells to cis-diamminedichloro-platinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55:590-596
33. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539
34. Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJS (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086
35. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95:5724-5729
36. O'Brien S, Kantarjian H, Keating M, et al. (1995) Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322-3326
37. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300
38. Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ (1999) Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399:708-712
39. Rhoads CP (1948) Report on a cooperative study of nitrogen mustard (HN2) therapy of neoplastic disease. Trans Assoc Am Physicians 60:110-117
40. Roboz J, Greaves J, Jui H, Holland JF (1982) Quantification of homoharringtonine and harringtonine in serum by chemical ionization mass spectrometry. Biomed Mass Spectrum 9:510-514
41. Russo D, Michelutti A, Melli C, et al. (1995) MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 9:513-516
42. Scherf U, Ross DT, Waltham M, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244
43. Schwartze MM, Hawley RG (1995) Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 55:2262-2265
44. Singh NP, D'Ambrosio SM (1984) Sister chromatid exchange frequency and cell cycle kinetics in cancer patients treated with cytostatic drugs. Basic Life Sci 29:885-893
45. Stoll SW, Benedict M, Mitra R, Hiniker A, Elder JT, Nunez G (1998) EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL. Oncogene 16:1493-1499
46. Wang ZH, Ding MX, Yuan JP, Jin ML, Hao CF, Chew-Cheng SB, Ng HK, Chew EC (1999) Expression of bcl-2 and Bax in EGFR-antisense transfected and untransfected glioblastoma cells. Anticancer Res 19:4167-4170
47. Wilkoff LJ, Dulmadge EA, Vasanthakumar G, Donahue JP (1993) Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine. Cancer Chemother Pharmacol 33:149-153
48. Zembutsu H, Ohnishi Y, Tsunoda T, et al. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anti-cancer drugs. Cancer Res 62:518-527